Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma
- 19 March 2008
- Vol. 112 (7), 1585-1591
- https://doi.org/10.1002/cncr.23332
Abstract
BACKGROUND. The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft‐tissue sarcomas (STS) treated on routine palliative protocols. METHODS. Patients with STS who had first‐line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database. Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study. RESULTS. In all, 488 patients (242 male, 246 female) fulfilled the study criteria. The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease. The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%). In all, 61% received single‐agent chemotherapy, usually doxorubicin. An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived ‘clinical benefit’ (objective responses + stable disease for ≥6 months). Median duration of response was 9 months and median posttreatment overall survival (OS) was 12 months. In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors. Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent. CONCLUSIONS. Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS. Synovial sarcoma and liposarcoma subtypes have a better prognosis. However, the overall poor outcome of these patients indicates the need to continue the search for more effective agents. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approachesCancer Treatment Reviews, 2006
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal of Cancer, 2005
- Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard CareThe Oncologist, 2005
- Soft-Tissue Sarcomas in AdultsThe New England Journal of Medicine, 2005
- Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden HospitalAnnals of Oncology, 2005
- Randomized Phase II Evaluation of 6 g/m2 of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m2 of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue SarcomaJournal of Clinical Oncology, 2005
- Systemic therapy of soft tissue sarcoma: an improvement in outcomeAnnals of Oncology, 2004
- Role of surgery as primary treatment and as intervention in the multidisciplinary treatment of soft tissue sarcomaAnnals of Oncology, 2004
- Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapyEuropean Journal of Cancer, 2003
- Management of soft-tissue sarcomas: an overview and updateThe Lancet Oncology, 2000